A detailed history of Ensign Peak Advisors, Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 24,920 shares of ARVN stock, worth $466,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,920
Previous 24,770 0.61%
Holding current value
$466,751
Previous $659,000 6.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $3,549 - $4,909
150 Added 0.61%
24,920 $613,000
Q1 2024

May 14, 2024

SELL
$36.38 - $52.31 $45,475 - $65,387
-1,250 Reduced 4.8%
24,770 $1.02 Million
Q3 2023

Nov 13, 2023

BUY
$19.64 - $28.21 $41,244 - $59,241
2,100 Added 8.78%
26,020 $511,000
Q2 2023

Aug 14, 2023

BUY
$21.73 - $31.43 $16,297 - $23,572
750 Added 3.24%
23,920 $593,000
Q1 2023

May 15, 2023

SELL
$26.15 - $37.26 $2.16 Million - $3.07 Million
-82,475 Reduced 78.07%
23,170 $633,000
Q4 2022

Feb 13, 2023

BUY
$32.47 - $57.24 $371,781 - $655,398
11,450 Added 12.16%
105,645 $3.61 Million
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $1.44 Million - $2 Million
34,403 Added 57.54%
94,195 $4.19 Million
Q2 2022

Aug 12, 2022

SELL
$36.01 - $74.24 $957,217 - $1.97 Million
-26,582 Reduced 30.78%
59,792 $2.52 Million
Q1 2022

May 16, 2022

BUY
$60.27 - $81.57 $282,184 - $381,910
4,682 Added 5.73%
86,374 $5.81 Million
Q4 2021

Feb 11, 2022

BUY
$65.85 - $96.21 $3.55 Million - $5.19 Million
53,952 Added 194.49%
81,692 $6.71 Million
Q3 2021

Nov 12, 2021

SELL
$73.2 - $107.87 $1.37 Million - $2.02 Million
-18,697 Reduced 40.26%
27,740 $2.28 Million
Q2 2021

Aug 13, 2021

BUY
$60.45 - $84.26 $2.5 Million - $3.49 Million
41,437 Added 828.74%
46,437 $3.58 Million
Q4 2020

Feb 12, 2021

BUY
$20.19 - $84.93 $100,950 - $424,650
5,000 New
5,000 $425,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.